Re Chalice [CHN]:
several factors contributed to Chalice Mining's significant share price decline:These factors combined led to a significant sell-off, with Chalice's shares falling approximately 70% since April 2023, despite the company's Gonneville deposit being considered one of Australia's most important critical metal projects
- High project costs: The scoping study revealed that developing the Gonneville deposit into an operating mine could cost between $1.6 billion to $2.3 billion, which was higher than some analysts expected.
- Delayed timeline: Chalice indicated it would not make a Final Investment Decision until 2026, with first production potentially not occurring until 2029. This extended timeline concerned investors.
- Commodity price assumptions: The scoping study relied on optimistic metal price assumptions, particularly for palladium. The study assumed $2,000 per ounce for palladium, while current prices are around half that amount.
- Transition from speculative to production-focused: Investors realized Chalice would shift from a speculative miner to a company tied to a productive asset, making it more susceptible to market realities like price fluctuations and demand changes.
- Potential dilution: There were concerns about substantial equity dilution and/or debt burden that could occur to finance the project.
- Short-selling pressure: Chalice has become a target for short-sellers, with 5.9% of its register in the hands of short-sellers. This has contributed to downward pressure on the stock price.
- Overall market sentiment: There has been a general lack of appetite for junior mining stocks, despite the critical role they play in future commodity supply chains.
- Forums
- ASX - By Stock
- DTR
- Ann: $1.66 million Rights Issue Shortfall Placed
DTR
dateline resources limited
Add to My Watchlist
2.35%
!
8.7¢

Ann: $1.66 million Rights Issue Shortfall Placed, page-47
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
8.7¢ |
Change
0.002(2.35%) |
Mkt cap ! $268.4M |
Open | High | Low | Value | Volume |
8.7¢ | 9.4¢ | 8.6¢ | $4.841M | 53.94M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 647141 | 8.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.8¢ | 221174 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 647141 | 0.087 |
11 | 566577 | 0.086 |
9 | 515035 | 0.085 |
3 | 299570 | 0.084 |
1 | 30000 | 0.083 |
Price($) | Vol. | No. |
---|---|---|
0.088 | 221174 | 5 |
0.089 | 208533 | 2 |
0.090 | 486391 | 6 |
0.091 | 392121 | 4 |
0.092 | 126163 | 3 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
DTR (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online